Visceral Leishmaniasis after Anti-Interleukin 17A (IL-17A) Therapy in a Patient Affected by Psoriatic Arthritis

The reactivation of latent <i>Leishmania</i> infection in chronic diseases and immunocompromised hosts is a broad and heterogeneous field in medicine and infectious diseases. We reported one of the first cases of Visceral Leishmaniasis occurring in a Caucasian middle-aged man living in a...

Full description

Bibliographic Details
Main Authors: Tommaso Lupia, Silvia Corcione, Valentina Fornari, Barbara Rizzello, Roberta Bosio, Maria Teresa Brusa, Francesco Giuseppe De Rosa
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:Tropical Medicine and Infectious Disease
Subjects:
Online Access:https://www.mdpi.com/2414-6366/7/10/319
Description
Summary:The reactivation of latent <i>Leishmania</i> infection in chronic diseases and immunocompromised hosts is a broad and heterogeneous field in medicine and infectious diseases. We reported one of the first cases of Visceral Leishmaniasis occurring in a Caucasian middle-aged man living in an endemic country (Italy) for <i>Leishmania infantum</i> infection following secukinumab treatment for psoriatic arthritis. The patient was cured with a Liposomal Amphotericin B (L-AmB, 3 mg/Kg on days 1–5, followed by a dose on days 10, 17, 24, 31 and 38) regimen, after which his anti-interleukin 17 treatment was restarted—without recurrence in the follow-up.
ISSN:2414-6366